Loading...

VBIO VALION BIO INC Management Changes 8-K Filing

VLN

VB

VALION BIO INC

(VBIO)

2026 8-K

Financial Results Update

Management Change

Company Name Change

Financial Results Report

Nasdaq Compliance Notification

Lease Agreements Announced

Meeting Cancelled

Leadership Change

Financial Statement Update

New Stock Agreement

Investor Presentation

Asset Acquisition

Tech Meeting Secured

Business Wind Down

Clinical Study Update

CEO Employment Agreement

Transfer Agent Change

IND Transfer Completed

Financial Results Report

Product Updates

Investor Meetings

Investor Meetings

Financial Statements

Equity Offerings

Equity Distribution

Nasdaq Compliance

License Agreement

Equity Purchase Agreement

New Data Release

Management Change

License Agreement

Stockholder Meeting

Nasdaq Compliance

Stockholder Letter

Q3 Financial Results

Clinical Approval

Strategic Partnership

Management Changes

Q2 Financial Results

Equity Incentive Plan

Termination of Agreement

Appointment and Resignation

Termination of Sublease Agr...

Collaboration Agreement

Securities Purchase Agreement

Earnings Release

Termination of Employment A...

Agreement with InStep health

Reverse Stock Split

Special Meeting of Stockhol...

Securities Purchase Agreement

US Patent Issuance

Delisting Notice

Equity Offerings

Annual Meeting Adjournment ...

Adjournment of Annual Meeting

Earnings Report

Resignation and Appointment

Research Collaboration Anno...

Financial Results and Corpo...

Public Offering

External Links:

Valion Bio, Inc. appointed Melinda Lackey as General Counsel and Senior VP on May 4, 2026, with a salary of $321,000 and options for 45,000 shares of stock at market value on the grant date.

AI Assistant

VALION BIO INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.